
    
      This will be a randomised, double blind, placebo controlled, parallel group evaluation of
      OC000459 given orally for eight days. Four dose levels will be studied and compared to
      placebo. They will be studied in treatment groups of 18 to 21 subjects. The placebo group
      will also consist of 18 to 21 subjects. There will be a screening period of up to six weeks.
      There will be a follow up one to three weeks after the last dose of study drug.
    
  